Opko, Pfizer deal

Opko granted Pfizer exclusive, worldwide commercialization rights to hGH-CTP to treat growth hormone deficiency (GHD) in adults and children and growth failure in children born small for their gestational age who fail to catch-up in growth by two years of age. Opko will receive $295 million up front and is eligible for up to $275 million in regulatory milestones. Opko is also eligible for royalties on the commercialization of hGH-CTP, which will transition to profit-sharing on both hGH-CTP and Pfizer’s Genotropin somatropin once hGH-CTP is launched to treat pediatric GHD. ...